Literature DB >> 31512959

Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia.

Jagdish Prasad Meena1, Megha Brijwal2, Rachna Seth1, Aditya Kumar Gupta1, Jyoti Jethani2, Arti Kapil2, Kana Ram Jat1, Aashish Choudhary2, S K Kabra1, S N Dwivedi3, Lalit Dar2.   

Abstract

Background: The role of respiratory viruses (RV) in children with cancer having febrile neutropenic episodes has not been well studied. The objectives of our study were to investigate the prevalence and clinical outcomes of Respiratory viral infection (RVI).
Methods: Children with cancer and febrile neutropenia (FN) having acute respiratory infections (ARI) were considered as cases and febrile neutropenic cancer patients without ARI were considered as controls. A throat swab sample was obtained for the detection of 21-respiratory pathogens.
Results: A total of 81 episodes of FN in cases and 37 episodes of FN in controls were included. Prevalence of RVI (at least 1 RV) was seen in 76.5% of cases and 48.6% of controls (p = 0.005). The mixed-respiratory viruses (co-infections of ≥2 viruses) were seen only in cases (26%) (p = 0.00). Rhinovirus (36.8%) and respiratory syncytial virus (13.6%) were the most frequently detected viruses. Median duration of fever before presentation was more in cases with RVI compared to without RVI [2 (1-5) days vs 1 (1-5) day (p = 0.012)]. The median total duration of febrile period was 4 (IQR, 3-6) days in cases with RVI and 3 (IQR, 1-4) days in cases without RVI (p = 0.005). The median duration of antibiotic days were longer in cases with RVI as compared to patients without RVI [9 (IQR, 7-17) days vs 7 (IQR, 6-10) days (p = 0.046)] respectively.
Conclusion: There was high prevalence of RVI in children with cancer and FN; more in association with ARI. The RVI were associated with prolonged febrile period and days of antibiotics therapy.

Entities:  

Keywords:  Respiratory viral infection; cancer; children; febrile neutropenia

Mesh:

Year:  2019        PMID: 31512959     DOI: 10.1080/08880018.2019.1631920

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia.

Authors:  Kaitlin Shinn; Martha Wetzel; Nicholas P DeGroote; Frank Keller; Michael Briones; James Felker; Sharon Castellino; Tamara P Miller
Journal:  Pediatr Blood Cancer       Date:  2020-09-02       Impact factor: 3.167

Review 2.  HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients.

Authors:  Cesar Martinez-Rodriguez; Ma Del Rocio Banos-Lara
Journal:  Pathogens       Date:  2020-01-10

Review 3.  Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients-A Systematic Review.

Authors:  Estera Boeriu; Alexandra Borda; Dan Dumitru Vulcanescu; Vlad Sarbu; Smaranda Teodora Arghirescu; Ovidiu Ciorica; Felix Bratosin; Iosif Marincu; Florin George Horhat
Journal:  Diagnostics (Basel)       Date:  2022-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.